The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States. Metabolic syndrome (MS) components are highly prevalent in NAFLD. Our aim is to assess the relationship of NAFLD and MS with long-term outcome of mortality.The Third National Health and Nutrition Examination Survey (NHANES) was utilized. NAFLD was diagnosed by ultrasound in the presence of hepatic steatosis and no other causes of chronic liver disease. History of MS and its components were obtained from self-reported NHANES questionnaires. Mortality was obtained from Mortality-Linkage File, through December 31, 2011. Chi-square test was used for categorical variables and Cox proportional models estimated hazard ratios with 95% confidence interval.NAFLD cohort (n = 3613) had a median age of 43 years, 73% white, and 50% male. NAFLD group with at least one MS condition was significantly older, had higher body mass index, more likely to have insulin resistance, and heart disease compared to NAFLD group without MS. Over 19-years of follow-up, 1039 people died. Compared to NAFLD patients without MS, presence of one MS component increased the risk of mortality at 8-year (2.6% vs 4.7%) and 16-year (6% vs 11.9%) (P < .001). After adjusting for socio-demographic factors, NAFLD with all MS components was associated with overall, cardiac and liver-mortality. Increased number of MS components was associated with lower survival (P < .0001).Patients with NAFLD and MS have higher mortality risk compared to NAFLD patients without MS. These NAFLD patients should be prioritized for the development of treatment regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, having several cardiometabolic risk factors confers a greater risk of progressive liver damage and major adverse liver outcomes. 17,35”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationEckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Self-citationEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D. B., Blissett, R., Henry, L. L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,308
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki‐Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,296
Kotronen, A., & Yki‐Järvinen, H. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 793
The Natural Course of Non-Alcoholic Fatty Liver Disease
Bertot, L. C., & Adams, L. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 638
Cited by
Sorted by citations
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Self-citationGlobal perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationEpidemiology of metabolic dysfunction-associated steatotic liver disease
Younossi, Z. M., Kalligeros, M., & Henry, L. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0431 · Cited by 960
Self-citationYounossi, Z., Stepanova, M., Ong, J., Jacobson, I., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V., Negro, F., Yılmaz, Y., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.05.057 · Cited by 702
Self-citationMortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021) · Gut · doi:10.1136/gutjnl-2020-322786 · Cited by 673
Younossi, Z. M., Corey, K. E., & Lim, J. K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.11.051 · Cited by 510
Self-citation(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Jarvis, H., Craig, D., Barker, R., Spiers, G., Stow, D., Anstee, Q. M., & Hanratty, B. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003100 · Cited by 434
Younossi, Z. M., Marchesini, G., Cortez‐Pinto, H., & Petta, S. (2018) · Transplantation · doi:10.1097/tp.0000000000002484 · Cited by 405
Self-citationChallenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Sun, E. J., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111639 · Cited by 292
Therapeutic pipeline in nonalcoholic steatohepatitis
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278
Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
Paik, J. M., Henry, L. L., de Avila, L., Younossi, E., Racila, A., & Younossi, Z. M. (2019) · Hepatology Communications · doi:10.1002/hep4.1419 · Cited by 226
Self-citationDifferential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD
Nguyen, V. H., Le, M. H., Cheung, R. C., & Nguyen, M. H. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.029 · Cited by 217
Harrison, S. A., Alkhouri, N., Davison, B. A., Sanyal, A., Edwards, C., Colca, J. R., Lee, B. H., Loomba, R., Cusi, K., Kolterman, O., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.023 · Cited by 211
Younossi, Z. M., Tampi, R. P., Racila, A., Qiu, Y., Burns, L. C., Younossi, I. M., & Nader, F. (2019) · Diabetes Care · doi:10.2337/dc19-1113 · Cited by 179
Self-citationCiaula, A. D., Baj, J., Garruti, G., Celano, G., Angelis, M. D., Wang, H. H., Palo, D. M. D., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082648 · Cited by 166
Arab, J. P., Dirchwolf, M., Álvares‐da‐Silva, M. R., Francisco Barrera, M., Benítez, C., Castellanos, M., Castro‐Narro, G., Chávez-Tapia, N. C., Chiodi, D., Cotrim, H. P., et al. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.09.006 · Cited by 146
Zhang, X., Wu, M., Liu, Z., Yuan, H., Wu, X., Shi, T., Chen, X., & Zhang, T. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-042843 · Cited by 132
Golabi, P., Paik, J. M., Reddy, R., Bugianesi, E., Trimble, G., & Younossi, Z. M. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-0972-6 · Cited by 127
Self-citationPreparing for the NASH Epidemic: A Call to Action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.074 · Cited by 127
Self-citationGolabi, P., Paik, J. M., Kumar, A., Al Shabeeb, R., Eberly, K. E., Cusi, K., GunduRao, N., & Younossi, Z. M. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155642 · Cited by 113
Self-citationMortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
Golabi, P., Paik, J. M., Arshad, T., Younossi, Y., Mishra, A., & Younossi, Z. M. (2020) · Hepatology Communications · doi:10.1002/hep4.1534 · Cited by 103
Self-citationRoeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 108
Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study
Niriella, M. A., Ediriweera, D. S., Kasturiratne, A., Silva, S. D., Dassanayaka, A. S., Silva, A. P. D., Kato, N., Pathmeswaran, A., Wickramasinghe, A. R., & de Silva, H. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245762 · Cited by 100
Abushamat, L. A., Shah, P. A., Eckel, R. H., Harrison, S. A., & Barb, D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.01.032 · Cited by 103
Younossi, Z. M., Corey, K. E., Alkhouri, N., Noureddin, M., Jacobson, I. M., Lam, B. P., Clement, S. C., Basu, R., Gordon, S. C., Ravendhra, N., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15830 · Cited by 92
Self-citationArshad, T., Paik, J. M., Biswas, R., Alqahtani, S. A., Henry, L. L., & Younossi, Z. M. (2021) · Hepatology Communications · doi:10.1002/hep4.1760 · Cited by 92
Self-citationLe, M. H., Le, D. M., Baez, T. C., Dang, H., Nguyen, V. H., Lee, K., Stave, C. D., Ito, T., Wu, Y., Yeo, Y. H., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0485 · Cited by 92
Younossi, Z. M., Stepanova, M., Anstee, Q. M., Lawitz, E., Wong, V. W., Romero‐Gómez, M., Kersey, K., Li, G., Subramanian, G. M., Myers, R. P., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.02.024 · Cited by 87
Self-citationBerardo, C., Pasqua, L. G. D., Cagna, M., Richelmi, P., Vairetti, M., & Ferrigno, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249646 · Cited by 89
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options
Younossi, Z. M., Stepanova, M., Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S. H., Shiffman, M. L., Schall, R. A., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.08.013 · Cited by 80
Self-citationUnderstanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Younossi, Z. M., & Henry, L. L. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0010 · Cited by 90
Self-citationGolabi, P., Paik, J. M., Eberly, K. E., de Avila, L., Alqahtani, S. A., & Younossi, Z. M. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100556 · Cited by 76
Self-citationGolabi, P., Paik, J. M., Harring, M., Younossi, E., Kabbara, K. W., & Younossi, Z. M. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.015 · Cited by 73
Self-citationHepatocellular carcinoma and non-alcoholic fatty liver disease
Golabi, P., Rhea, L. P., Henry, L. L., & Younossi, Z. M. (2019) · Hepatology International · doi:10.1007/s12072-019-09995-8 · Cited by 73
Self-citationNonalcoholic Fatty Liver Disease: Current Global Burden
El‐Kassas, M., Cabezas, J., Iruzubieta, P., Zheng, M., Arab, J. P., & Awad, A. (2022) · Seminars in Liver Disease · doi:10.1055/a-1862-9088 · Cited by 73
Elsaid, M. I., Li, Y., Bridges, J. F. P., Brock, G., Minacapelli, C. D., & Rustgi, V. K. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.35003 · Cited by 63
Spearman, C. W., Afihene, M., Betiku, O., Bobat, B., Cunha, L., Kassianides, C., Katsidzira, L., Desalegn, H., Ocama, P., Ojo, O., et al. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00275-2 · Cited by 63
Golabi, P., Fukui, N., Paik, J. M., Sayıner, M., Mishra, A., & Younossi, Z. M. (2019) · Hepatology Communications · doi:10.1002/hep4.1387 · Cited by 61
Self-citationGolabi, P., Paik, J. M., Hwang, J. P., Wang, S., Lee, H. M., & Younossi, Z. M. (2018) · Liver International · doi:10.1111/liv.14038 · Cited by 60
Self-citationPaik, J. M., Duong, S., Zelber‐Sagi, S., Lazarus, J. V., Henry, L. L., & Younossi, Z. M. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002749 · Cited by 60
Self-citationMAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease
Huang, J., Ou, W., Wang, M.-F., Singh, M., Liu, Y., Liu, S., Wu, Y., Zhu, Y., Kumar, R., & Lin, S. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s285880 · Cited by 58
Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population
Arshad, T., Golabi, P., Paik, J. M., Mishra, A., & Younossi, Z. M. (2018) · Hepatology Communications · doi:10.1002/hep4.1285 · Cited by 55
Self-citationPoor Sleep Is Related to Metabolic Syndrome Severity in Adolescents With PCOS and Obesity
Simon, S. L., Rahat, H., Carreau, A., Garcia‐Reyes, Y., Halbower, A. C., Pyle, L. L., Nadeau, K. J., & Cree‐Green, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz285 · Cited by 54
Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis
Liu, B., Li, Y., Li, Y., Liu, Y., Yan, Y., Luo, A., Ren, H., & She, Q. (2019) · Hepatology International · doi:10.1007/s12072-019-09972-1 · Cited by 52
Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease.
Ballestri, S., Mantovani, A., Nascimbeni, F., Lugari, S., & Lonardo, A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0003 · Cited by 35
Younossi, Z. M., Stepanova, M., Younossi, I. M., & Racila, A. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.01.001 · Cited by 51
Self-citationDietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data
Paik, J. M., Mir, S., Alqahtani, S. A., Younossi, Y., Ong, J. P., & Younossi, Z. M. (2021) · Hepatology Communications · doi:10.1002/hep4.1707 · Cited by 50
Self-citationClusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome
Wittwer, J. A., & Bradley, D. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.612496 · Cited by 51
Johnston, M. P., Patel, J. A., & Byrne, C. D. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200128094231 · Cited by 49
Tampi, R. P., Wong, V. W., Wong, G. L., Shu, S. S., Chan, H. L., Fung, J., Stepanova, M., & Younossi, Z. M. (2020) · Hepatology Research · doi:10.1111/hepr.13535 · Cited by 49
Self-citationBalak, D., Piaserico, S., & Kasujee, I. (2021) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s342911 · Cited by 52
Głuszyńska, P., Lemancewicz, D., Dzięcioł, J. B., & Hady, H. R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245721 · Cited by 51
Preparing for the NASH Epidemic: A Call to Action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0020 · Cited by 47
Self-citationBdh1 overexpression ameliorates hepatic injury by activation of Nrf2 in a MAFLD mouse model
Xu, B.-T., Teng, F., Wu, Q., Wan, S., Li, X., Tan, X., Xu, Y., & Jiang, Z. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00840-w · Cited by 48
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 44
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154822 · Cited by 46
Self-citationThe grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease
Kim, Y.-K., Kwon, O.-S., & Her, K. H. (2019) · Medicine · doi:10.1097/md.0000000000016018 · Cited by 42
Golabi, P., Owrangi, S., & Younossi, Z. M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17833 · Cited by 45
Self-citationRoderburg, C., Krieg, S., Krieg, A. H., Demir, M., Luedde, T., Kostev, K., & Loosen, S. H. (2023) · European journal of medical research · doi:10.1186/s40001-023-01114-6 · Cited by 41
Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment
Molina‐Molina, E., Krawczyk, M. J., Stachowska, E., Lammert, F., & Portincasa, P. (2019) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2019.04.005 · Cited by 40
Sayıner, M., Arshad, T., Golabi, P., Paik, J. M., Farhat, F., & Younossi, Z. M. (2020) · Hepatology International · doi:10.1007/s12072-020-10038-w · Cited by 40
Self-citationRenaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?
Lonardo, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030492 · Cited by 38
Colca, J. R., & Scherer, P. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101409 · Cited by 39
Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression
Thandra, K. C., Barsouk, A. A., Saginala, K., Aluru, J. S., Rawla, P., & Barsouk, A. (2020) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2020.102153 · Cited by 34
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks
Cheung, A. C., & Ahmed, A. (2021) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s226130 · Cited by 38
von Loeffelholz, C., Roth, J., Coldewey, S. M., & Birkenfeld, A. L. (2021) · Biomedicines · doi:10.3390/biomedicines9121853 · Cited by 36
Ahmad, M. I., Khan, M. U., Kodali, S., Shetty, A., Bell, S. M., & Victor, D. W. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s344559 · Cited by 36
Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness
Golabi, P., Va, I., & Younossi, Z. M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.001 · Cited by 35
Self-citationComprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
Josloff, K., Beiriger, J., Khan, A., Gawel, R. J., Kirby, R. S., Kendrick, A. D., Rao, A. K., Wang, R. X., Schafer, M., Pearce, M. E., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120419 · Cited by 35
Nonalcoholic steatohepatitis: global impact and clinical consequences
Kabbara, K. W., Golabi, P., & Younossi, Z. M. (2021) · Endocrine Connections · doi:10.1530/ec-21-0048 · Cited by 33
Self-citationHan, M. A. T., Yu, Q., Tafesh, Z., & Pyrsopoulos, N. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00082 · Cited by 33
The Impact of Obesity and Type 2 Diabetes on Chronic Liver Disease
Younossi, Z. M., & Henry, L. L. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000433 · Cited by 32
Self-citationSarcopenia, healthy living, and mortality in patients with chronic liver diseases
Dongen, C. V., Paik, J. M., Harring, M., Younossi, Y., Price, J. K., Kabbara, K. W., Golabi, P., & Younossi, Z. M. (2022) · Hepatology Communications · doi:10.1002/hep4.2061 · Cited by 31
Self-citationAuthors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Wang, Y., Zhu, K.-F., Zhou, W., Zhang, Q., Deng, D., Yang, Y., Xu, J. X., Xu, J. X., & Yang, Y. (2021) · BMC Geriatrics · doi:10.1186/s12877-020-01910-3 · Cited by 30
Hashem, A., Shastri, Y., Otaibi, M. A., Buchel, E., Saleh, H., Ahmad, R., Ahmed, H., Idris, F. A., Ahmed, S., Guda, M. F., et al. (2021) · Gastroenterology Insights · doi:10.3390/gastroent12020014 · Cited by 30
Pereira, E. N. G. D. S., Paula, D. P., de Araujo, B. P., da Fonseca, M. D. J. M., Diniz, M. D. F. H. S., Daliry, A., & Griep, R. H. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i29.4913 · Cited by 27
Payne, J. Y., Alkhouri, N., Le, P., Rothberg, M. B., Polanco, P., Sakkal, C., & Dasarathy, S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000019 · Cited by 28
Pustjens, J., van Kleef, L. A., Janssen, H. L. A., de Knegt, R. J., & Brouwer, W. P. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101193 · Cited by 29
Epidemiology of NAFLD – Focus on diabetes
Younossi, Z. M., & Henry, L. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111648 · Cited by 26
Self-citationDarmian, M. A., Hoseini, R., Amiri, E., & Golshani, S. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-00970-z · Cited by 25
Blaszczak, A. M., Krishna, S. G., Hart, P. A., Bradley, D. P., Hsueh, W. A., Lara, L. F., Hussan, H., Hinton, A. M., Conwell, D. L., & Cruz‐Monserrate, Z. (2020) · Pancreatology · doi:10.1016/j.pan.2020.08.011 · Cited by 25
Sakuma, T., Nakamura, M., Chiba, T., Iwanaga, T., Kan, M., Kojima, R., Ao, J., Ma, Y., Unozawa, H., Fujita, N., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00807-6 · Cited by 24
Nonalcoholic fatty liver disease from a primary care perspective
Clark, J. M., Cryer, D. R. H., Morton, M., & Shubrook, J. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15016 · Cited by 26
Carretero, R. G., Vigil, L., Barquero‐Pérez, Ó., & Ramos, J. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0052 · Cited by 23
Vahedi, H., Atefi, M., Entezari, M. H., & Hassanzadeh, A. (2022) · Trials · doi:10.1186/s13063-022-06451-1 · Cited by 23
Wang, T., Xi, Y., Raji, A., Crutchlow, M. F., Fernandes, G. F., Engel, S. S., & Zhang, X. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101154 · Cited by 25
Li, M., Chen, W., Deng, Y., & Xie, W. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.018 · Cited by 22
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 23
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Younossi, Z. M., de Avila, L., Petta, S., Hagström, H., Kim, S. U., Nakajima, A., Crespo, J., Castéra, L., Alkhouri, N., Zheng, M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001564 · Cited by 20
Self-citationXiang, W., Yang, Y., Weng, L., Ye, Z., Ding, P., Li, H., Sun, J. Y., & Zeng, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110085 · Cited by 20
Sogabe, M., Okahisa, T., Kurihara, T., Takehara, M., Kagemoto, K., Okazaki, J., Kida, Y., Hirao, A., Tanaka, H., Tomonari, T., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238388 · Cited by 20
Younossi, Z. M., Pham, H., Felix, S. C., Stepanova, M., Jeffers, T., Younossi, E., Allawi, H., Lam, B. P., Cable, R., Afendy, M., et al. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000340 · Cited by 20
Self-citationPaudel, M. S., Tiwari, A., Mandal, A., Shrestha, B., Kafle, P., Chaulagai, B., & Sudhamshu, K. C. (2019) · Cureus · doi:10.7759/cureus.4099 · Cited by 20
Metadata
- Authors
- Golabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M.
- Affiliations
- Inova Health System (US)
- Corresponding author
- Younossi, Zobair M.
- Venue
- Medicine
- Published
- 2018-03
- Volume
- 97
- Issue
- 13
- Pages
- e0214
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC5895395
- OpenAlex
- W2794816422
- Cited by
- 221
- References
- 46
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 32 · 2023: 25 · 2022: 33 · 2021: 36 · 2020: 24 · 2019: 24 · 2018: 9
- FWCI
- 18.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-sa
- Locations
- Medicine (publishedVersion, cc-by-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-sa)
- PubMed Central (publishedVersion, cc-by-sa)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, metabolic syndrome, mortality risk, hepatic steatosis, insulin resistance, cardiovascular mortality, liver-related mortality, body mass index, long-term survival
- MeSH terms
- Adult, Cardiovascular Diseases, Female, Humans, Insulin Resistance, Male, Middle Aged, Nutrition Surveys, Risk Factors, United States, Comorbidity, Body Mass Index, Proportional Hazards Models, Age Distribution, Sex Distribution, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review